featured
Adjuvant Ipilimumab for High-Risk Melanoma: Pros and Cons
Written by
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3(3):483-490.
- Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67(4):228-233.
- American Cancer Society. Cancer facts & figures 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Updated 2013. Accessed April 19, 2015.
- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
- Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [published online March 31, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)70122-1.